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ABSTRACT 
Background: CT-perfusion (CTP) and MRI may assist patient selection for 
endovascular thrombectomy. We aimed to establish whether imaging assessments 
of ischaemic core and penumbra volumes were associated with functional outcomes 
and treatment effect. 
 
Methods: In this systematic review and meta-analysis, we pooled patient-level data 
from all randomised controlled trials comparing endovascular thrombectomy using 
predominantly stent-retrievers with medical therapy in anterior circulation ischaemic 
stroke listed in Pubmed 1/Jan/2010-31/May/2017 (HERMES Collaboration). The 
primary outcome was functional outcome as assessed by the modified Rankin scale 
(mRS) at 90 days.  Irreversibly injured ischaemic core was estimated as CTP relative 
cerebral blood flow<30% of normal brain or MRI apparent diffusion co-efficient 
threshold<620m2/s. Hypoperfused tissue-at-risk of infarction was estimated using 
CTP time-to-maximum (Tmax)>6s. Mismatch (estimated penumbral) volume was 
calculated as tissue-at-risk minus core volume. The association of pre-treatment core 
and penumbral volumes with 90-day mRS was analysed with multivariable logistic 
regression (functional independence; defined as mRS 0-2) and ordinal logistic 
regression (functional improvement by at least 1 mRS category) in all patients and 
those with >50% endovascular reperfusion, adjusted for baseline prognostic 
variables. The meta-analysis was prospectively designed, but not registered. 
 
Findings: We identified 7 studies with 1764 patients, all were included in the meta-
analysis. Pre-treatment CTP was available for 591(34%) and MRI for 309(18%) . 
Since functional independence was worse in patients who had pre-treatment CTP 
versus MRI, after adjustment for ischaemic core volume [odds ratio 0·47(0·30,0·72), 
p=0·0007], the modalities were not pooled. Increasing ischaemic core volume was 
associated with reduced likelihood of functional independence [CTP adjusted 
OR=0·77(0·69-0·86) per 10mL, p(interaction)=0·29; MRI adjusted OR=0·87(0·81-
0·94) per 10mL], p(interaction)=0·94. CTP mismatch volume was not associated with 
outcome. In CTP-imaged patients with >50% endovascular reperfusion, age(OR 
0·83(0·72-0·94), p=0·005), ischaemic core volume(OR 0·82 (0·73-0·92), p=0·001), 
and imaging-to-reperfusion time(OR 0·79 (0·66-0·95), p=0·01) were independently 
associated with functional outcome in ordinal logistic regression. 
 
Interpretation: Estimated ischaemic core volume was independently associated with 
outcome but did not modify treatment effect. Combining ischaemic core volume with 
age and expected imaging-to-reperfusion time will improve assessment of prognosis 
and may inform treatment decisions.  
 
Funding: Medtronic. 
 
Research in context 
Evidence before this study 
We did a systematic review of studies in any language in PubMed between 
1/Jan/2010-31/May/2017 examining the prognostic effect of penumbral imaging 
parameters including estimated ischaemic core volume and penumbral mismatch 
volume in patients with stroke undergoing endovascular stent-thrombectomy using 
one of the search terms “penumbral imaging” OR “mismatch” OR “ischaemic core” 
OR “diffusion” AND either “endovascular” OR “thrombectomy” OR “intra-arterial”. The 
prospective, observational DEFUSE 2 study showed improved outcomes in patients 
with the penumbral mismatch profile  (which required an ischaemic core volume 
<70mL) who reperfused (n=46) versus those who not reperfuse (n=32, OR 8·8, 
95%CI 2·7-29·0) but there was not a significant benefit of reperfusion in patients 
without the favourable penumbral mismatch profile (n=21, OR 0·2, 95%CI 0·0-1·6). 
Two small retrospective studies suggested that reperfusion may benefit patients with 
large cores defined as either >70mL on diffusion MRI or extensive non-contrast CT 
hypodensity defined as Alberta Stroke Program Early CT Score (ASPECTS) 0-5. 
Subanalysis of 175 patients imaged with pre-treatment CTP in the MR CLEAN trial 
showed that >70mL ischaemic core volume was associated with less favorable 
prognosis without loss of benefit from thrombectomy, with strength and precision of 
findings limited by sample size. 
Added value of this study 
This individual patient-level analysis of 1764 patients quantifies the independent 
prognostic effect of ischaemic core volume on functional outcome. A 10mL increase 
in ischaemic core volume had a similar adverse impact on functional outcome as a 
30 minute delay in imaging-to-reperfusion time or a 5 year increase in age. However, 
the odds of improved outcome and absolute benefit (ie, number needed to treat) from 
treatment with thrombectomy were maintained in patients over a wide range of 
ischaemic core volumes.  
 
Implications of all the available evidence 
Patients should not be excluded from endovascular thrombectomy within 6 hours of 
stroke onset purely on the basis of a large estimated ischaemic core. The patient’s 
age and functional status, their views on disability outcomes (if known) and the 
expected time to achieve reperfusion should be considered alongside ischaemic core 
volume when estimating the attainable outcome and determining the most 
appropriate treatment. 
  
Introduction 
Individual patient data meta-analysis of endovascular thrombectomy after large-
vessel ischaemic stroke demonstrated remarkable consistency in treatment effect 
across clinical subgroups, although age and clinical severity remained strongly 
prognostic8 and treatment effect declined with delayed reperfusion.9 However, the 
positive trials of endovascular thrombectomy 0-6h after ischaemic stroke onset used 
different clinical and brain imaging selection criteria.1-7 Imaging selection for 
ischaemic stroke treatment aims to identify individual pathophysiology, rather than 
traditional group-average time thresholds.10  
 
The presence of ischaemic penumbra (electrically non-functioning but metabolically 
viable brain tissue that is salvageable with rapid blood flow restoration) forms the 
rationale for reperfusion therapies. Patients have marked variation in collateral blood 
flow (via leptomeningeal anastomoses and other pathways) that maintains penumbra 
distal to an arterial occlusion.11,12 Penumbral imaging with CT-perfusion (CTP) or 
multimodal MRI, when processed in a reproducible manner using validated 
thresholds, can estimate both the irreversibly injured ischaemic core and potentially 
salvageable ischaemic penumbra with reasonable accuracy.13-16 The mismatch 
between the hypoperfused tissue-at-risk (or territory of the occluded artery) and the 
ischaemic core estimates the salvageable penumbra. 
 
The DAWN17 and DEFUSE318 trials demonstrated benefit of thrombectomy beyond 
6h in patients with favourable CTP or MR penumbral imaging. However, the role of 
penumbral imaging selection within 6h of stroke onset remains uncertain. Patients 
estimated to have a large ischaemic core are sometimes excluded from reperfusion 
therapies2-5 and the thrombectomy trials used variable non-contrast CT, CT-
angiographic collaterals, CTP and multimodal MRI criteria. There are limited data 
characterising clinical benefit of endovascular thrombectomy as ischaemic core 
volume increases. The DEFUSE2 prospective cohort study demonstrated benefit of 
endovascular reperfusion in patients with favourable perfusion-diffusion MRI (criteria 
included diffusion lesion volume<70mL).12 No benefit was observed among patients 
without the favourable imaging profile. In contrast, two retrospective observational 
studies suggested benefit of reperfusion in patients with MRI-diffusion 
lesions>70mL19 or Alberta Stroke Program Early Computed Tomography Score 
(ASPECTS)<6 which correlates with large ischaemic core.20 Sub-analysis of pre-
treatment CTP from MR-CLEAN (n=175) found no interaction between ischaemic 
core volume and treatment effect.21  
 
We did a systematic review and meta-analysis of all randomised controlled trials of 
stent-retriever thrombectomy versus medical therapy within 6h published between 
1/01/2010 and 31/05/2017 to assess the influence of ischaemic core volume 
(estimated using CTP and MRI-diffusion), and the volume of hypoperfused tissue-at-
risk (estimated using CTP) on functional outcome after thrombectomy.  
 
Methods 
Search strategy and selection criteria  
This study was a systematic review and meta-analysis, performed according to 
PRISMA guidelines, comparing endovascular thrombectomy predominantly 
performed with stent-retrievers versus medical therapy in patients with anterior 
circulation ischaemic stroke. We searched PubMed for randomised controlled trials 
published in any language between 1/01/2010 and 31/05/2017 using the search 
string ((“randomized controlled trial” [Publication Type]) AND 
((thrombectomy[Title/Abstract]) OR (clot retrieval[Title/Abstract]) OR 
intraarterial[Title/Abstract]) AND (stroke[Title/Abstract])). Individual patient-level data 
from the identified trials: MR-CLEAN,1 EXTEND-IA,2 ESCAPE,3 SWIFT-PRIME,4 
REVASCAT,5 PISTE6 and THRACE7 were pooled in the Highly Effective Reperfusion 
using Multiple Endovascular Devices (HERMES) collaboration.8 All participants 
provided informed consent according to each trial protocol and each study was 
approved by the local ethics board. The meta-analysis was prospectively designed 
by the HERMES executive committee, but not registered. The protocol is available in 
the appendix.  
 
Data analysis 
Statistical analysis was performed using SAS v.9.4 (SAS Institute, Cary, NC, USA) 
and R version 3.3 (R Foundation for Statistical Computing, Vienna, Austria). 
Qualitative assessment of between-trial differences including patient eligibility and 
assessment of bias are presented in appendix.  
An independent core laboratory (Los Angeles, USA) collated imaging data, assigning 
a random HERMES ID to blind assessors to trial of origin. Individual CTP and MRI-
diffusion data were uniformly reprocessed using RAPID software (v4.6, 
iSchemaView, Menlo Park, California) as used in EXTEND-IA2 and SWIFT-PRIME.4 
All automated output was visually verified and artefacts removed by a stroke 
neurologist with extensive neuroimaging analysis experience, blinded to treatment 
allocation and all other imaging and clinical information. For CTP, irreversibly injured 
ischaemic core was estimated as relative cerebral blood flow<30% of normal brain.13 
For MRI-diffusion, ischaemic core was defined using apparent diffusion co-efficient 
(ADC)<620m2/s.22 Tissue-at-risk of infarction was estimated using CTP-Tmax>6s.23 
Penumbral mismatch volume was calculated as the difference between Tmax>6s 
and ischaemic core lesion volumes and penumbral mismatch ratio as Tmax>6s 
divided by ischaemic core lesion volume.  
 
The primary outcome was modified Rankin scale (mRS) at 90 days. Regression 
analyses were adjusted for 7 baseline prognostic variables: age, sex, baseline 
clinical severity (National Institutes of Health Stroke Scale (NIHSS) score), time from 
stroke onset-to-randomisation, administration of intravenous alteplase, core-lab-
adjudicated noncontrast-CT ASPECTS, and site of vessel occlusion. To account for 
between-trial variance we used mixed-effects modeling with a random effect for trial 
incorporated in all models. The interaction between ischaemic core volume and 
treatment was tested by including the multiplicative volume-by-treatment term in 
regression models.   
 
The effect of CTP versus MRI modality on the prognostic effect of ischaemic core 
volume was first tested in logistic regression for functional independence (mRS 0-2) 
and ordinal logistic regression for the 6-level mRS (merging categories 5-6). Since 
imaging modality was a prognostic factor, these data were treated separately for the 
main analysis. The treatment effect in the prespecified subgroups with ischaemic 
core volume <70mL vs >70mL was examined using ordinal logistic regression (6-
level mRS). Symptomatic intracerebral haemorrhage was assessed as a safety 
outcome using the definitions applied in the original trials (appendix).  
 
The effects of ischaemic core volume, time-to-treatment (onset-to-imaging and 
imaging-to-reperfusion time) and clinical prognostic variables (age, sex, NIHSS, 
intravenous thrombolysis) on functional outcome were examined in the subgroup of 
patients with >50% endovascular reperfusion using multivariable logistic regression.  
 Modeling of the effect of ischaemic core and penumbral mismatch volumes on 
functional outcome was performed using mRS0-2 (functional independence) and the 
utility-weighted mRS score, a patient-centered, linear disability measure that converts 
each mRS score to a utility score between 1(perfect health) and 0(death)24: mRS 
0=1, mRS 1=0·91, mRS 2=0·76, mRS 3=0·65, mRS 4=0·33, mRS 5=0, mRS 6=0. 
Reduction in utility score can therefore be expressed as a percentage increased 
disability.  
 
The number needed to treat (NNT) to achieve mRS 0-1, 0-2, 0-3 or at least 1 unit 
improvement in mRS with endovascular treatment versus control was calculated for a 
range of ischaemic core volumes, based on model-derived adjusted treatment effects 
(absolute risk reduction). NNT was calculated as 1/absolute risk reduction. 
The association between pre-treatment ischaemic core and penumbral mismatch 
volumes and the 90-day mRS was examined by treatment status. The subgroup with 
>50% endovascular reperfusion (post-procedure, core-lab adjudicated, modified 
Treatment in Cerebral Infarction (mTICI)2b-3) was also examined.25  
 
 
Role of the funding source 
The funder of this study had no role in study design, data collection, data analysis, 
data interpretation, or the writing of the report. The corresponding author had full 
access to all the data in the study and had final responsibility for the decision to 
submit for publication. 
 
Results  
Of 1764 patients included in the 7 RCTs, penumbral imaging was performed and 
assessable in 900(51%). Pre-treatment CTP was obtained in 625(35%) and 
assessable in 591(34%) after exclusion of 34 patients (11 severe motion, 7 no lesion 
within coverage, 2 contrast bolus failure, 14 data corruption during transfer from site). 
Of the 591 patients, 289(49%) were randomised to endovascular thrombectomy and 
302(51%) to control group. Baseline characteristics were similar between 
endovascular and control patients with pre-treatment CTP (table 1). Median CTP-
estimated ischaemic core volume was 10mL(IQR 3-28mL), appendix). Pre-treatment 
MRI-diffusion was obtained in 309/1764(18%) patients, 153/309(50%) randomised to 
endovascular thrombectomy and 156/309(50%) to control group. No significant 
differences were observed in baseline characteristics between endovascular and 
control patients with pre-treatment MRI-diffusion. Median MRI-diffusion estimated 
ischaemic core volume was 21mL(IQR 10-52mL, appendix). Imaging was performed 
within 6h of stroke onset in 887/900(99%) patients. MRI-perfusion was available for 
only 33 patients and was not analysed.  
 
In logistic regression, ischaemic core volume was associated with reduced 
independent functional outcome (OR 0·85, 95%CI 0·80-0·90, p<0·0001) and worse 
outcome in ordinal logistic regression analysis of mRS (cOR 0·86 95%CI 0·83-0·89, 
p<0·0001), per 10mL increase, after adjustment for the 7 prespecified covariates and 
imaging modality (CTP or MRI). Imaging modality was independently associated with 
reduced independent functional outcome (OR 0·47, 95%CI 0·30-0·72, p=0·0007) and 
worse outcome in ordinal logistic regression analysis of mRS (cOR 0·51 95%CI 0·36-
0·72, p=0·0001). There was no interaction between imaging modality and treatment 
effect (p=0·86), indicating that the relative effect on outcome per 10mL increase in 
core was consistent between modalities. Given these differences in predicted 
functional outcome modeled on core volume between the MRI and CTP groups, 
these data were not pooled for subsequent analyses. 
 
Larger ischaemic core volume estimated using CTP was associated with lower 
probability of independent functional outcome (mRS0-2) in endovascular (OR 0·79 
95%CI 0·69-0·90) and control patients (OR 0·71 95%CI 0·56-0·90) per 10mL 
increase in volume in the 7-covariate adjusted model. Benefit from thrombectomy 
was not modified by ischemic core volume (core*treatment interaction p=0·29, figure 
1). When ASPECTS (which was correlated with ischaemic core volume but not 
independently associated with outcome) was omitted from the model the 
core*treatment interaction remained non-significant (p=0·26). In a multivariable 
logistic regression model including both endovascular and control patients, a 10mL 
increase in ischaemic core volume was associated with reduced odds of independent 
functional outcome (OR 0·77, 95%CI 0·69-0·86) with the other significant covariates 
being age, baseline NIHSS, endovascular treatment, onset-to-randomisation time, 
and site of vessel occlusion but not ASPECTS (appendix). The odds ratio relating 
core volume to independent functional outcome was similar in the subgroup of 
endovascular patients with >50% reperfusion (n=186, OR 0·83 95%CI 0·71-0·97 per 
10mL increase in ischaemic core volume). At 100mL ischaemic core volume, the 
absolute increase in independent functional outcome was 25.4%, 95%CI 0.8-49.9% if 
endovascular reperfusion was achieved versus the control group. 
 
Larger CTP-estimated ischaemic core volume was also associated with worse 
disability outcome using utility-weighted mRS. Utility was significantly reduced by 3%, 
95%CI 1-4% per 10mL increase in ischaemic core volume for endovascular patients 
and by 2%, 95%CI 1-3% for control patients. Though prognostically important, 
ischaemic core volume did not modify the benefit from thrombectomy (core*treatment 
interaction p=0·23, or p=0·51 when ASPECTS was omitted, figure 1). In 
endovascular-treated patients with >50% reperfusion (n=186), utility was significantly 
reduced by 3%, 95%CI 1-5% per 10mL increase in ischaemic core volume 
(appendix). In ordinal logistic regression including both endovascular and control 
patients, ischaemic core volume had cOR 0·85, 95%CI 0·81-0·91 per 10mL increase 
with the other significant covariates being age, baseline NIHSS, endovascular 
treatment and site of vessel occlusion (appendix). 
 
In the pre-planned subgroup analysis of patients with ischaemic core >70mL using 
CTP (n=50, median 100mL(IQR 82-144mL), 2(8%) of 25 thrombectomy and 
0/25(0%) control patients achieved functional independence (OR infinite). 
Thrombectomy patients had improved functional outcome in unadjusted ordinal 
logistic regression analysis of the mRS: cOR 3·1 95%CI 1·0-9·4 (figure 2). However, 
despite similar age in both treatment groups, NIHSS was higher in the control group 
than in the thrombectomy group (median 22 versus 18, p=0·005) and the ischaemic 
core volume was numerically larger in controls than in the thrombectomy patients 
(median 110mL versus 85mL, p=0·12, ASPECTS 5 versus 8, p=0·001). There was 
insufficient sample size to include the full 7-co-variates in the >70mL subgroup but 
adjustments for age and NIHSS resulted in cOR 1·8, 95%CI 0·3-12·5, p=0·53. In this 
subgroup, there was no difference in symptomatic intracerebral haemorrhage 
between endovascular patients 0/25(0%) versus 3/25(12%) control patients, p=0·24 
(appendix).  
 
MRI-diffusion lesion volume was independently associated with independent 
functional outcome in endovascular (OR 0·88, 95%CI 0·78-0·97) and control patients 
(OR 0·87 95%CI 0·79-0·96) per 10mL increase in volume (figure 1, appendix) but did 
not significantly interact with thrombectomy treatment effect (p=0·94). Similarly, 
increasing MRI-diffusion lesion volume was independently associated with a 
reduction in utility score in endovascular (2%, 95%CI 1-3%) and control patients (2%, 
95%CI 1-3%) per 10mL increase in volume; p-interaction=0·58. The relationship 
between ischaemic core and functional outcome in endovascular patients with >50% 
reperfusion (n=186) was similar to that observed in the CTP reperfusion subgroup 
(appendix). Patients with >70mL MRI-diffusion lesions (n=59) achieved functional 
independence in 7/23(30%) thrombectomy versus 7/36(20%) control group (OR 1.8, 
95%CI 0.5-6.3, cOR 2.1, 95%CI 0.8-5.6, unadjusted, Figure 2). 
 
Increasing CTP ischaemic core volume was not associated with a significant 
reduction in absolute treatment effect or increased NNT, assessed using common 
dichotomies and ordinal logistic regression analysis of mRS (Figure 3).  Notably the 
lower confidence interval for treatment effect in ordinal analysis remained >0 for 
ischaemic core volumes up to 150mL. The NNT point estimate remained less than 10 
for most outcomes and less than 5 for ordinal shift in patients with ischaemic core 
volumes up to ~125mL, noting wide confidence intervals.  Absolute risk reduction by 
MRI-diffusion lesion volume and NNT is displayed in the appendix. 
 
In multivariable logistic regression analysis within the CTP-imaged, endovascular-
treated patients who achieved >50% reperfusion (n=186), age, imaging-to-
reperfusion time and ischaemic core volume were associated with both ordinal 
improvement in mRS and functional independence (table 2). Surface plots display 
the effect of age and imaging-to-reperfusion time on functional outcome for a given 
CTP ischaemic core volume in patients with >50% endovascular reperfusion (figure 
4).   
 
The median volume of CTP penumbral mismatch was 96mL(IQR 64-138mL), 0-10ml 
was present in 5 patients (<1%), 10-60ml in 125 (21%) patients, and ≥60ml in 453 
(78%) patients. Motion artefacts excluded 8/591(1.4%) patients from this analysis. 
The median penumbral mismatch ratio was 9·4(IQR 3·6-33·7), 556/583(95)% had a 
ratio>1·8 as originally applied in SWIFT PRIME and 580/583(99·5%) had a ratio>1·2 
as applied in EXTEND-IA. CTP penumbral mismatch volume was correlated with 
ischaemic core volume (rho=0·13, p=0·002). In univariate analysis, CTP penumbral 
mismatch volume was associated with ordinal mRS (OR per 10ml=0·96, 95%CI 0·93-
0·99, p=0·009) and utility-weighted mRS (beta per 10ml=-0·007, 95%CI -0·011 to -
0·002, p=0·001) but not functional independence (OR per 10ml=0·97, 95%CI 0·93-
1·00, p=0·08). When ischaemic core volume was included in the model, mismatch 
was not associated with either outcome (utility-weighted mRS beta per 10ml=-0·001, 
95%CI -0·006 to 0·004, p=0·60, mRS0-2 OR per 10ml=1·01, 95%CI 0·97-1·05, 
p=0·65).  
 
There were 34/583(6%) patients with no CTP penumbral mismatch by SWIFT PRIME 
criteria (14 in the endovascular group and 20 in the control group). These patients 
had no benefit from endovascular treatment (cOR 0·87, 95%CI 0·20-3·81, p=0·85) in 
a model adjusted for ischaemic core volume. Ischaemic core volume remained 
prognostic in this group (cOR 0·78, 95%CI 0·67-0·90, p=0·002). The interaction 
between CTP penumbral mismatch status and endovascular treatment effect was not 
significant (p=0·15), although power was limited by the small number of patients 
without penumbral mismatch. 
 Discussion  
Larger estimated ischaemic core volume was independently associated with worse 
outcome in patients treated with endovascular thrombectomy and in those who 
received medical therapy. Every 10ml increase in pretreatment ischaemic core 
volume reduced the odds of favourable outcomes by 20-30%. However, large 
ischaemic core did not prevent benefit of endovascular thrombectomy versus medical 
therapy in patients who otherwise met eligibility for these trials. At every ischaemic 
core volume level, favorable outcomes were more likely with thrombectomy than with 
medical care alone. Favourable functional outcomes among thrombectomy patients 
were associated with age, ischaemic core volume (reflecting accumulated injury 
before imaging) and time from imaging-to-reperfusion (reflecting additional injury 
before reperfusion). This combination of prognostic factors may inform more 
individualized decision-making in patients with larger ischaemic core volumes. The 
volume of mismatch between the ischaemic core and hypoperfused Tmax>6s lesion 
was not associated with outcomes independent of ischaemic core volume and did not 
interact with treatment effect. However, few patients had no mismatch and there was 
no signal of benefit from endovascular thrombectomy in this group.  
 
The early time window and imaging selection approaches used in many of the 
included trials, resulted in a modest number of patients with large ischaemic cores, 
even in this large pooled dataset, and the power to probe for treatment effect 
modification by ischaemic core volume was constrained. Moreover, similar odds 
ratios (and hence lack of statistical interaction) can mask substantial differences in 
absolute treatment effect, which may be clinically relevant. Importantly, the absolute 
benefit and number needed to treat point estimates for different functional outcomes 
across the spectrum of ischaemic core volumes remained clinically meaningful. In 
ordinal analysis of the modified Rankin scale, confidence intervals indicated that a 
clinically significant benefit of at least 1 point improvement was maintained up to 
approximately 150mL of CT/MRI ischaemic core volume. In addition, there was no 
signal of harm as symptomatic intracerebral haemorrhage was not increased in 
patients with large ischaemic core in the included trials.  
 
In patients with >50% endovascular reperfusion, the key prognostic variables were 
age, ischaemic core volume and imaging-to-reperfusion delay. When CTP ischaemic 
core volume was included in the multivariable model it was strongly related to 
functional outcome, non-contrast CT ASPECTS was no longer associated with 
outcome and the effect of stroke onset-to-imaging time became weak and of 
borderline significance. This reflects the benefits of directly assessing the extent of 
ischaemic injury that can be highly variable between patients, despite similar time 
elapsed from stroke onset. The impact of a 10mL increase in ischaemic core volume 
was approximately equivalent to a 30min delay in imaging-to-reperfusion or a 5yr 
increase in age. Chronological age is not an ideal selection criterion and 
physiological robustness and functional reserve may be more valid in clinical 
practice, albeit harder to quantify objectively. Our data illustrate the principle that 
weighing patient functional status, the volume of irreversible injury at the time of 
imaging and the expected time to achieve reperfusion (particularly when transfer to 
another hospital may be required) can improve patient selection for endovascular 
thrombectomy. The importance of faster workflow to reduce treatment delay is 
particularly evident for patients with a large ischaemic core.  
 
There has been debate about the relative merits of CTP versus MRI as initial imaging 
strategy and, indeed, whether either is useful for endovascular thrombectomy 
selection within 6h of stroke onset.24 In contrast, penumbral imaging is central to 
selecting patients who benefit from thrombectomy beyond 6h.17,18 However, our data 
demonstrate strong prognostic relationships that substantially improve estimation of 
outcome versus non-contrast CT and clinical variables. As illustrated in figure 4, the 
absolute probability of meaningful improvement in a patient with a large ischaemic 
core, in addition to clinical poor prognostic factors, may be sufficiently low that 
thrombectomy may be regarded as futile, even within 6h of stroke onset.  
 
Interestingly, CTP and MRI ischaemic core volume versus outcome curves were 
offset (MRI was associated with better outcome at any estimated core volume). 
However, the lack of statistical interaction indicated that the prognostic influence per 
mL increase in ischaemic core was similar. Whether this modality difference occurred 
due to underestimation of infarct volume by CTP, overestimation by DWI, a trial-
specific effect (with the majority of MRI data coming from a single trial) or some 
combination of these factors remains unclear. Regardless, there was no evidence of 
a difference in prognostic accuracy between MRI and CTP.  
 
Study limitations include that CTP was not required in all trials and therefore imaging 
acquisition protocols varied. Overestimation of the actual core volume could 
potentially explain good outcome in some patients with large estimated ischaemic 
core. However, analyses using follow-up infarct volume in this dataset,26 SWIFT 
PRIME27 and EXTEND-IA2 showed substantial overestimation of the core volume 
using CTP processed with RAPID was rare. RAPID software has been used in 
multiple trials and its accuracy is well described.12,27-29 Results using other software 
packages vary substantially30 and our findings may not apply. The majority of MRI 
data came from one trial (THRACE). Although all analyses were adjusted by trial, 
some residual trial effect may have persisted in the MRI data. The component trials 
were of high quality and risk of bias was overall assessed to be low, apart from the 
unblinded outcome assessment in THRACE. The multivariable model for favourable 
outcome among CTP-imaged patients with >50% reperfusion and figure 4 were 
based on 186 patients. Collection of large patient datasets with baseline CTP and 
MRI-diffusion, successful reperfusion, and 90 day functional outcomes is desirable to 
validate and improve precision of the prognostic model.  
 
In conclusion, this large series of patients with pre-treatment CTP and MRI-diffusion 
demonstrated the potential for clinically meaningful benefit in patients with large 
baseline ischaemic core when treated within 6h of stroke onset. This was particularly 
evident in younger patients with fast imaging-to-reperfusion times. Patients should 
therefore not be excluded from therapy solely based on large ischaemic core. Clinical 
judgment is required based on the individual patient’s overall health status, location 
of the core relative to highly eloquent structures, the time to expected reperfusion 
and, where known, the patient’s attitudes to different potential disability states. 
Further study of the risk and benefit of endovascular reperfusion in patients with large 
ischaemic core at initial imaging is crucial to ensure that thrombectomy is available to 
the broadest possible range of appropriate large vessel ischaemic stroke patients 
with potential to benefit. 
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Figure legends 
 
Figure 1: Association of ischaemic core volume with functional outcome. 
CT perfusion (CTP) ischaemic core volume versus A) functional independence, B) 
disability (utility scores derived from modified Rankin Scale (mRS). 
MRI ischaemic core volume versus C) functional independence,  D) disability. Point 
estimate (solid) and 95% confidence interval (dashed), models adjusted for age, sex, 
baseline clinical severity (National Institutes of Health Stroke Scale (NIHSS) score), 
time from stroke onset to randomisation, administration of intravenous alteplase, 
core-lab-adjudicated noncontrast CT ASPECTS, site of vessel occlusion with a 
random effect for trial. 
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Figure 2: Functional outcome at day 90 stratified by ischaemic core volume 
A) CTP ischaemic core volume </> 70mL B) MRI ischaemic core volume </>70mL. 
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Figure 3: Treatment effect of endovascular thrombectomy versus medical 
therapy by CTP ischaemic core volume A) excellent functional outcome (mRS 0-
1), B) functional independence (mRS 0-2) C) mRS 0-3, D) improvement by at least 1 
mRS category (point estimate and 95% confidence interval). N=591 patients. NNT - 
number needed to treat. Models adjusted for age, sex, baseline clinical severity 
(National Institutes of Health Stroke Scale (NIHSS) score), time from stroke onset to 
randomisation, administration of intravenous alteplase, core-lab-adjudicated 
noncontrast CT ASPECTS, site of vessel occlusion with a random effect for trial. 
 
  
Figure 4: Effect of CT perfusion ischaemic core volume, age and imaging-to-
reperfusion time on functional outcome after endovascular reperfusion. 
 90 day functional outcome dichotomized at A) modified Rankin scale (mRS) 0-2 and 
B) mRS 0-3 in patients who had >50% endovascular reperfusion (n=186) see 
expanded figure in appendix. Patients with small (10mL) ischaemic core often 
achieve functional independence (mRS 0-2) despite advanced age and/or extended 
delays between imaging and reperfusion. Patients with large (75mL) or very large 
(125ml) ischaemic core are unlikely to achieve functional independence unless 
reperfusion is achieved very shortly after imaging (panel A). However, many patients 
would prefer mild disability (mRS 3) to nursing home care or death and this is 
achievable, even for relatively elderly patients with large ischaemic core, if rapid 
reperfusion is possible (panel B). 
 
 
Table 1: Baseline characteristics of patients 
Characteristic 
CTP MRI Overall 
HERMES 
(n=1764) 
Endovascular 
(n=289) 
Control  
(n=302) 
Endovascular 
(n=153) 
Control 
(n=156) 
Age mean  65·5 (13·7) 65·7 (13·0) 63·1 (13·1) 63·6 (14·0) 65·6 (13·5) 
Sex 
Male 
Female  
 
137 (47%)  
152 (53%) 
 
168 (56%)  
134 (44%) 
 
94 (61%) 
59 (39%) 
 
73 (47%) 
83 (53%) 
 
929 (53%) 
835 (47%) 
Initial NIHSS median  
17  
(14-20) 
17  
(13-21) 
18  
(14-21) 
17  
(14-21) 
17  
(13-21) 
Initial ASPECTS 
median  
8 (7-9) 8 (7-9) 7 (6-8) 7 (5-8) 8 (7-9) 
Site of arterial occlusion  
79 (27%) 
171 (59%) 
28 (10%) 
11 (4%) 
 
78 (26%)  
189 (63%) 
24 (8%) 
11 (4%) 
 
25 (16%) 
112 (73%) 
5 (3%) 
11 (7%) 
 
33 (21%) 
101 (65%) 
8 (5%) 
14 (9%) 
 
442 (25%) 
1073 (61%) 
131 (7%) 
116 (7%) 
ICA 
M1 
M2 
Unknown 
Onset to ED (min) 
median  
110  
(57-183) 
110  
(54-197) 
105  
(75-139) 
110  
(80-159) 
105  
(60-180) 
ED to arterial access 
(min) median  
103 (75-150) NA 107 (85-140) NA 115 (80-165) 
Received IV Alteplase  248 (86%) 269 (89%) 145 (95%) 154 (99%) 1572 (89%) 
Baseline ischaemic core 
volume (mL) median  
10 (3-30) 9 (2·5-24) 18 (9-41) 23 (12-63) NA 
Baseline Tmax>6s 
perfusion volume (mL) 
median  
122 (79-165) 123 (82-167) NA NA NA 
 
Data are mean (SD), median (IQR), or n (%). NIHSS is a standardised neurological examination for which the score ranges from normal (0) 
to death (42). ASPECTS reflects the extent of early ischaemic change on the CT brain; 10 is normal, 0 shows involvement of the entire 
middle cerebral artery territory. CTP=CT perfusion. NIHSS=National Institutes of Health Stroke Scale. ASPECTS=Alberta stroke program 
early CT score. ICA=internal carotid artery. M1=first segment of middle cerebral artery (pre-bifurcation). M2=second segment of middle 
cerebral artery (from bifurcation to the circular sulcus of the insula in the Sylvian fissure). ED=emergency department. IV=intravenous. 
NA=not applicable 
  
Table 2: Independent functional outcome in patients imaged with CT-perfusion who achieved >50% 
endovascular reperfusion 
Predictor among patients with 
endovascular reperfusion (n=186) 
Multivariable ordinal logistic regression mRS 0-2 (multivariable logistic 
regression) 
cOR (95%CI) P value OR  (95%CI) P value 
Age (per 5 years) 0·83 (0·72-0·94) 0·005 0·81 (0·69-0·96) 0·02 
NIHSS (per 5 points) 0·83 (0·60-1·14) 0·25 0·59 (0·41-0·87) 0·008 
Women (vs men) 0·54 (0·31-0·96) 0·04 0·80 (0·41-1·56) 0·52 
tPA delivered (vs not) 0·75 (0·31-1·76) 0·50 0·84 (0·30-2·34) 0·75 
Onset to imaging (per 30 min) 0·92 (0·84-1·00) 0·06 0·89 (0·80-0·99) 0·04 
Imaging to reperfusion (per 30 min) 0·79 (0·66-0·95) 0·01 0·74 (0·57-0·96) 0·02 
Ischaemic core volume  
(per 10 ml) 
0·82 (0·73-0·92) 0·001 0·77 (0·67-0·90) 0·001 
 
 
